To Top

Search By Topic

Clinical Trial

299 Articles available

Myopia

SightGlass Vision Multicenter Trial to Study Novel Eyeglasses to Control Nearsightedness for FDA Approval

PR-M01-19-NI-040

Investment

New Opioid-alternative Raises $3.25 Million for Phase I Trials

PR-M01-19-NI-037

Clinical Trials

Initial Positive Results Lead to Expanded Cancer Trial

PAO-M01-19-NI-006

Oncology

Innovent Announces First Patient Dosed in a Phase III Clinical Trial of Anti-PD-1 Antibody Tyvyt® (Sintilimab injection) as First-line Treatment for Patients with Advanced Esophageal Cancer

PR-M01-19-NI-012

Press Releases

Innovent Announces First Patient Dosed in a Phase III Clinical Trial of Anti-PD-1 Antibody Tyvyt®

Oncology

Rakuten Aspyrian Enrolling Phase 3 Trial of ASP-1929 for Head and Neck Cancer

PR-M12-18-NI-086

Clinical Trial Patient Populations

Amgen And Lazarex Cancer Foundation Team Up To Allow More Diversity In Clinical Trials

PR-M12-18-NI-059

Drug Development

Alligator Bioscience Starts Clinical Phase I Study With ATOR-1015

PR-M12-18-NI-054

Alzheimer's Disease

First Drug Candidate From Eisai-UCL Research Collaboration To Enter Alzheimer's Disease Clinical Trials

PR-M12-18-NI-037

Clinical Trial

Prometic to Initiate PBI-4050 Pivotal Phase 3 Clinical Trial in Alström Syndrome

PR-M12-18-NI-028

Leukemia

Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

PR-M12-18-NI-025

Clinical Trials

Late-Breaking Clinical Trials Advance Targeted Therapies for Patients with CLL and Multiple Myeloma

PR-M12-18-NI-018

Bispecific Antibody

Regeneron’s Bispecific Antibody Candidate Shows Positive Results in Early Clinical Studies

PAO-M12-18-NI-007

Clinical Trial

First Trial Launches to Test Effectiveness of Male Contraceptive Gel

PR-M12-18-NI-001

Respiratory

Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-8236, a Novel Inhaled pan-JAK Inhibitor

PR-M11-18-NI-102

Clinical Trial

QPS Expands U.S.-Based Phase I Clinical Trial Capabilities to Support the Growing Needs of Its Pharmaceutical, Biotechnology and CRO Partners

PR-M11-18-NI-098

Crohn's Disease

Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-1473 in Patients with Crohn's Disease

PR-M11-18-NI-092

Clinical Trial

Auritec Pharmaceuticals Completes Enrollment for its Sustained-release Depot Tacrolimus Clinical Trial

PR-M11-18-NI-078

Clinical Trial

Promentis Pharmaceuticals Announces Successful Completion of Phase 1 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism

PR-M11-18-NI-084

Clinical Trials

Sollis Therapeutics Announces the First Patient Enrolled in a Phase 3 Clinical Trial of Clonidine Micropellet for Sciatica

PR-M11-18-NI-078

Clinical Trials

AIVITA Biomedical Announces Treatment of First Two Patients in Phase 2 Glioblastoma Trial

PR-M11-18-NI-073

Clinical Trials

Phase III Study Results for Peanut Allergy Therapy Are a Mixed Bag

PAO-M11-18-NI-021

Clinical Data

DNAtrix To Present Interim Phase 2 Results of DNX-2401 with Pembrolizumab for Glioblastoma

PR-M11-18-NI-067

Clinical Study

Pulmatrix to Present Results from the Pulmazole (PUR1900) Phase 1/1b Study at 2018 Annual Scientific Meeting

PR-M11-18-NI-063

Clinical Trial

OncoSec Doses First Patient in KEYNOTE-890 Phase 2 Clinical Trial

PR-M11-18-NI-044

Clinical Trial Data

BD Announces Clinical Trial Data for the LUTONIX® 014 Drug-Coated Balloon Below-The-Knee IDE Trial

PR-M11-18-NI-041

Respiratory

Gala Enrolls First Subjects in an Early Feasibility Study of RheOx™ for Chronic Bronchitis in the United States

PR-M11-18-NI-023

Clinical Trials

Lipocine Announces Completion of Enrollment in LPCN 1144 Liver Imaging Study in Subjects At-Risk for NASH

PR-M11-18-NI-022

Cholesterol

Third PCSK9 Inhibitor for Lowering Cholesterol Moves into Phase III Trials

PAO-M11-18-NI-005

Osteoarthritis

High-Valued Start-Up Announces Positive Results for Osteoarthritis Drug

PAO-M11-18-NI-003

Macular Degeneration

More Positive Results for Novartis Eye Drug Brolucizumab

PAO-M11-18-NI-002

Hepatitis

MYR Pharma Announces Presentation of Interim Results of MYR 203, a Phase 2 Study of Myrcludex in Combination with Pegylated Interferon in Chronic Hepatitis Delta

PR-M10-18-NI-107

Crohn's

Salix And Alfasigma Will Initiate Late-Stage Program To Study Rifaximin In Patients With Postoperative Crohn's Disease

PR-M10-18-NI-106

Diabetes

ActoBio Therapeutics™ Doses First Patient in Phase Ib/IIa Clinical Study of AG019 for the Treatment of Type 1 Diabetes

PR-M10-18-NI-105

Clinical Trials

RegeneRx Partner Updates on Clinical Trials

PR-M10-18-NI-102

Clinical Trials

Medicenna Presented Insights from the Phase 2b Clinical Trial of MDNA55 at the European Society for Medical Oncology 2018 Congress

PR-M10-18-NI-091

PR-M10-18-NI-081

BiondVax Receives €8M From the European Investment Bank (EIB) in Support of Manufacturing Facility and Ongoing Phase 3 Clinical Trial

Investment

Oncology

Real-world Study Shows Sequencing of Gilotrif® Followed by Osimertinib Delivered a Combined Median Time on Treatment

PR-M10-18-NI-080

Clinical Trials

Reistone Biopharma, a New Chinese Biotech Company Ready to Initiate its Ulcerative Colitis Phase II Clinical Trial Globally

PR-M10-18-NI-076

Clinical Trials

Ward MM and Endocanna Health Announce Partnership Supporting Medicinal Cannabis Clinical Trials

PR-M10-18-NI-074

Clinical Data

Janssen Announces New Three-Year TREMFYA® (Guselkumab) Data Demonstrates Stably Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis

PR-M10-18-NI-073

Antibiotics

PolyPid Begins Phase 2 Study to Assess Safety and Efficacy of D-PLEX100 in Prevention of Abdominal Surgical Site Infections

PR-M10-18-NI-070

ADHD

Aevi Genomic Medicine Announces Completion of Enrollment for Part B of the ASCEND Trial

PR-M10-18-NI-066

Stem Cells

Cellect Announces Positive Clinical Results

PR-M10-18-NI-065

Biosimilars

Innovent Receives IND Approval to Initiate Clinical Trials in China with Sintilimab in Combination with its Biosimilar to Bevacizumab

PR-M10-18-NI-056

Clinical Trials

New Diabetes Drug Shows Promise in Phase 2 Study

PAO-M10-18-NI-012

Oncology

Targovax Reports Encouraging Disease-free Survival (DFS) Data From Tg01 Trial in Resected Pancreatic Cancer

PR-M10-18-NI-055

Clinical Trials

OncoSec Initiates KEYNOTE-890, a Phase 2 Clinical Trial of TAVO in Combination with Merck's KEYTRUDA®

PR-M10-18-NI-053

Phase 3

Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301

PR-M10-18-NI-054

Clinical Trials

New Clinical Trial Will Evaluate Biomarkers as Predictors of Treatment Response in IBD

PAO-M10-18-NI-009

Clinical Study

Allergan Launches Personalized Study Approach for Clinical Research Programs in Inflammatory Bowel Disease

PR-M10-18-NI-024

Vaccine

Promising Phase 2b Results for New GSK Tuberculosis Vaccine

PAO-M10-18-NI-002

Clinical Data

One-Year Results from Real-World Study Showed Abbott's Portico™ Transcatheter Aortic Valve Safely and Successfully Reduced Severe Aortic Stenosis

PR-M10-18-NI-003

FDA

FDA Removes Partial Clinical Hold on Tazemetostat Clinical Trials

PAO-M09-18-NI-024

Clinical Trial

Xeris Pharmaceuticals and OHSU Conducting Artificial Pancreas Clinical Trial Using Xeris’ Novel Ready-to-Use Liquid Glucagon

PR-M09-18-NI-066

Clinical Trial

Trovagene Announces Completion of Second Dosing Cohort of Patients Treated with Onvansertib (PCM-075) in Ongoing Phase 1b/2 AML Trial

PR-M09-18-NI-061

Clinical Results

Biohaven Reports Positive Results From Double-Blind, Placebo-Controlled, Investigator Initiated, Proof Of Concept Trial Of BHV-0223 For Anxiety

PR-M09-18-NI-060

Drug Development

Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2018 World Congress on Parkinson's Disease and Related Disorders

PR-M09-18-NI-058

Study Results

Regeneron and Teva Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip

PR-M09-18-NI-059

Phase II

Peptide Logic Awarded A $ 2.9 Million SBIR Phase II Grant To Develop Peripherally-Restricted And Long-Acting Kappa-Opioid Receptor (LA-KOR) Agonists For Moderate-To-Severe Pain

PR-M09-18-NI-056

Study Results

Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip

PR-M09-18-NI-051

Clinical Data

Actinium to Provide Update on Pivotal Phase 3 SIERRA Trial Following Positive Data Monitoring Committee Meeting

PR-M09-18-NI-043

Study Results

Janssen Reports Positive Topline Results for ATLAS Phase III Study of a Novel, Long Acting Injectable Two-Drug Regimen for the Treatment of HIV-1

PR-M09-18-NI-045

Phase 2

Oragenics, Inc. Resumes Phase 2 Clinical Trial of AG013 in Oral Mucositis Following Positive Routine Safety Review

PR-M09-18-NI-041

Research

Novocure and US Oncology Research Announce Collaboration on PANOVA-3 Trial for Patients with Advanced Pancreatic Cancer

PR-M09-18-NI-040

Oncology

CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study

PR-M09-18-NI-038

Clinical Study

Electromed, Inc. Announces Results of an Independent Clinical Study: Bronchiectasis Exacerbations Reduced, Lung Function Stabilized with SmartVest®

PR-M09-18-NI-037

Preclinical Data

Synlogic Publishes Preclinical Data Supporting Development of SYNB1618, a Synthetic Biotic™ Medicine as a Potential Treatment for Phenylketonuria

PR-M09-18-NI-026

Clinical Trials

Entasis Therapeutics Announces Positive Topline Results from Phase 2 Trial of ETX2514SUL in Patients with Complicated Urinary Tract Infections including Acute Pyelonephritis

PR-M09-18-NI-024

Biosimilar

JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Bevacizumab Biosimilar to Treat Lung Cancer

PR-M09-18-NI-013

Clinical Trial

First Patient Dosed in Phase 1/2 Study Evaluating SOBI003 for Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)

PR-M09-18-NI-012

Clinical Use

Conavi Medical Announces Clinical Use of the Novasight Hybrid System with Simultaneous Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT) Capabilities

PR-M09-18-NI-009

Phase I

Samsung Bioepis to Initiate Phase 1 Clinical Trial of SB26 Ulinastatin-Fc Fusion Protein

PR-M09-18-NI-007

Clinical Trials

GI Dynamics Announces FDA Approval for EndoBarrier Pivotal Trial

PR-M09-18-NI-006

Clinical Trial

Enrollment Passes Halfway Milestone in Clinical Trial Evaluating the Effect of an Exclusive Human Milk Diet

PR-M08-18-NI-122

Study Results

VolitionRx Limited Announces Completion of Sample Collection in Endometriosis Study

PR-M08-18-NI-119

Clinical Trial

I-Mab's Announces China Clinical Trial Approval of Long-acting hGLP-1 to Treat Type 2 Diabetes

PR-M08-18-NI-116

FDA Guidance

FDA Published Draft Guidance on Use of Placebo Control Groups

PAO-M08-18-NI-029

Clinical Data

Novartis Reports Promising Results for its New Alpha Specific PI3K Inhibitor BYL719

PAO-M08-18-NI-028

Clinical Trial

Sangamo Announces Positive Preliminary Data from the Phase 1/2 Alta Study Evaluating SB-525 Gene Therapy for Hemophilia A

PR-M08-18-NI-113

Clinical Trial

Clovis Oncology Announces First Patient Enrolled in the Phase 3 ATHENA Trial

PR-M08-18-NI-085

Clinical Trial

Milestone Pharmaceuticals Announces First Patient Randomized in the Phase 3 NODE-301 Clinical Trial Evaluating Etripamil for Termination of Paroxysmal Supraventricular Tachycardia (PSVT) Episodes

PR-M08-18-NI-098

Clinical Trial

First Participant Enrolled in BiondVax's Universal Flu Vaccine Pivotal Phase 3 Clinical Trial

PR-M08-18-NI-095

Supply Chain

Marken Offers First Hybrid Service from Brazil to USA

PR-M08-18-NI-124

Clinical Trials

60 Day Window for Clinical Trial Approval Official, says George Clinical, a leading Asia-Pacific CRO

PR-M08-18-NI-123

Clinical Trials

Xcovery Announces First Cohort of Patients Dosed in a Phase 1/2 Clinical Trial of Vorolanib

PR-M08-18-NI-035

Opening

DPS Group and TRIA Celebrate Opening of State-of-the-Art cGMP mRNA Clinical Manufacturing Facility for Moderna Therapeutics

PR-M07-18-NI-077

Clinical Trials

Allergan and Molecular Partners Announce Two Positive Phase 3 Clinical Trials

PR-M07-18-NI-067

Announcement

Cook® Regentec Announces First U.S. Clinical Use of Advance® CS Coronary Sinus Infusion Catheter to Deliver a Therapeutic in Heart Failure Patients

PR-M07-18-NI-063

Phase 3

PainReform Gets FDA Approval for Phase III Post-Operative Pain Relief Study

PR-M07-18-NI-062

Clinical Data

Eisai Inc. Announces Positive Topline Results from CAMELLIA-TIMI 61, a Large-Scale Cardiovascular Outcome Trial for the Anti-Obesity Agent BELVIQ®

PR-M07-18-NI-056

FDA Approval

U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

PR-M07-18-NI-047

Diabetes

Diabetes Research Institute Launches New Clinical Trial to Explore Effects of Omega-3 Fatty Acids and Vitamin D in Type 1 Diabetes

PR-M07-18-NI-043

Clinical Trials

CStone's PD-1 inhibitor CS1003 receives clinical trial approval in China

PR-M07-18-NI-042

Clinical Research

Eating Well Might Improve Cancer Treatments

PAO-M07-18-NI-006

Drug Development

SCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal Candidiasis

PR-M07-18-NI-039

Clinical Study

BioArctic Receives Regulatory Approval in Finland for a Clinical Study in Patients With Complete Spinal Cord Injury

PR-M07-18-NI-033

Oncology

Phase III IMpassion130 study showed Roche’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening for metastatic triple negative breast cancer

PR-M07-18-NI-021

Clinical Data

Mallinckrodt Rheumatoid Arthritis Phase 4 Clinical Study for H.P. Acthar® Gel (Repository Corticotropin Injection) Achieves its Enrollment Target

PR-M07-18-NI-009

Biosimilars

Amgen Announces Top-Line Results From Phase 3 Study Of ABP 710, Biosimilar Candidate To Infliximab

PR-M06-18-NI-100

Clinical Trials

Javara Launches Next Generation Integrated Clinical Trials Platform

PR-M06-18-NI-088

Clinical Trials

Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases

PR-M06-18-NI-091

Press Releases

Arcus Biosciences and Infinity Pharmaceuticals Announce Clinical Collaboration to Evaluate Lead Programs in Triple-Combination Studies

Clinical Data

Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In

PR-M06-18-NI-086

Clinical Trials

Oramed Enrolls First Patient in Its Glucose Clamp Study for Oral Insulin

PR-M06-18-NI-083

Clinical Trials

Aminex Therapeutics Initiates First Clinical Trial of Novel Immunotherapy AMXT 1501 + DFMO in Cancer Patients

PR-M06-18-NI-072

Clinical Trials

Array BioPharma to Present Overall Survival Results from the Phase 3 LUNGevity Takes Step Forward in Clinical Trial Eligibility Reform for Lung Cancer Patients

PR-M06-18-NI-062

Clinical Data

Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL

PR-M06-18-NI-062

Clinical Trials

BioMarin Doses First Participant in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia

PR-M06-18-NI-059

Clinical Trials

Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meeting

PR-M06-18-NI-060

Trial Results

Merck KGaA, Darmstadt, Germany Provides Update on Tepotinib Phase II Results in Advanced Hepatocellular Carcinoma

PR-M06-18-NI-041

Clinical Data

More Positive Phase 3 Results for Roche’s Tecentriq

PAO-M05-18-NI-024

Clinical Trials

Supporting Patient-Centric Clinical Trials from Point-of-Origin through the Last Mile

PAP-Q2-18-CL-002

Clinical Trials

Splash Pharmaceuticals Announces Dose Escalation in Phase I Clinical Trial in Platinum-resistant Ovarian Cancer Patients

PR-M05-18-NI-109

Clinical Trial

Sanofi: Accelerating Future Breakthroughs Through Clinical Trials -- Part 2 of 3

PR-M05-18-NI-080

Clinical Trial

Research Ready™ Program Expands and Diversifies Clinical Trial Patient Populations

PR-M05-18-NI-065

Oncology

Roche’s TECENTRIQ (Atezolizumab) Receives Priority Review

PAO-M05-18-NI-009

Clinical Trials

Merck Provides Update on KEYNOTE-407 Trial

PR-M05-18-NI-026

Clinical Data

Study Shows AST-005 is Safe and Tolerable in Patients at Higher Doses than Previously Studied

PAO-M05-18-NI-003

Clinical Data

DiscGenics Announces First Patient Treated in U.S. Clinical Trial of IDCT for Degenerative Disc Disease

PR-M04-18-NI-004

Clinical Trials

Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home

PR-M04-18-NI-100

Clinical Trials

AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients

PR-M04-18-NI-102

Vaccine

Vaccibody moving forward with Cancer Neoantigen Vaccine Trial

PR-M04-18-NI-79

Clinical Trials

Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery

PR-M04-18-NI-51

FDA

Kadmon Receives FDA Guidance on Pivotal Clinical Trial Design for KD025 in Chronic Graft-Versus-Host Disease

PR-M04-18-NI-46

Oncology

New Breast Cancer Drug Accepted for Review by EMA

PAO-M04-18-NI-010

Clinical Trials

Eli Lilly Gets Good News for Cyramza

PAO-M04-18-NI-009

Clinical Trials

First Patient Treated in Pivotal Phase 3 Trial to Evaluate OTL38 in the Detection of Ovarian Cancer

PR-M04-18-NI-33

Clinical Trials

SELLAS Life Sciences Announces Positive Interim Data from Phase 2b NeuVax™ (nelipepimut-S) Clinical Trial

PR-M04-18-NI-020

Results

Allergan and Richter Announce Positive Topline Results from Third of Three Pivotal Trials of Cariprazine in Bipolar I Depression

PR-M04-18-NI-018

Results

Positive Results for Pfizer Drug Tafamidis

PAO-M04-18-NI-001

Clinical Trials

MediciNova Announces Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD will be Terminated Early based on Significant Positive Results from Interim Analysis

PR-M04-18-NI-014

Clinical Trials

Pfizer Announces Positive Topline Results From Phase 3 ATTR-ACT Study Of Tafamidis In Patients With Transthyretin Cardiomyopathy

PR-M04-18-NI-006

Clinical Trials

Wize Pharma Enrolls First Patient in Phase IV Study of LO2A for Symptomatic Treatment of Dry Eye Syndrome in Patients With Sjögren's Syndrome

PR-M04-18-NI-005

Clinical Trials

Final results from landmark DYNAGITO® trial published in The Lancet Respiratory Medicine

PR-M04-18-NI-001

Clinical Data

Clinical Study Data for New MS Drug Looks Promising

PR-M03-18-NI-101

Clinical Trials

BrainStorm Cell Therapeutics' Phase 3 Trial of NurOwn® in ALS Now Open to Canadian Patients

PR-M03-18-NI-108

Clinical Data

New Study finds younger aged children with symptoms of ADHD have reduced brain size

PR-M03-18-NI-101

Clinical Trials

Clinical Trial Access to Expand Following Receipt of Additional Funding

PAO-M03-18-NI-026

Ipsen

Ipsen Receives Positive CHMP Opinion for Cabometyx® (cabozantinib) for the First-Line Treatment of Adults with Intermediate- or Poor- Risk Advanced Renal Cell Carcinoma

PR-M03-18-NI-096